Home › Compare › TBGNF vs VICI

TBGNF vs VICI: Dividend Comparison 2026

TBGNF yields 1176.47% · VICI yields 6.57%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TBGNF wins by $78814194.21M in total portfolio value
10 years
TBGNF
TBGNF
● Live price
1176.47%
Share price
$0.17
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78814195.20M
Annual income
$67,523,701,253,088.38
Full TBGNF calculator →
VICI
VICI Properties Inc.
● Live price
6.57%
Share price
$27.12
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$988.8K
Annual income
$623,261.32
Full VICI calculator →

Portfolio growth — TBGNF vs VICI

📍 TBGNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTBGNFVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TBGNF + VICI cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
TBGNF pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TBGNF
Annual income on $10K today (after 15% tax)
$100,000.00/yr
After 10yr DRIP, annual income (after tax)
$57,395,146,065,125.13/yr
VICI
Annual income on $10K today (after 15% tax)
$558.67/yr
After 10yr DRIP, annual income (after tax)
$529,772.12/yr
At 15% tax rate, TBGNF beats the other by $57,395,145,535,353.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TBGNF + VICI for your $10,000?

TBGNF: 50%VICI: 50%
100% VICI50/50100% TBGNF
Portfolio after 10yr
$39407098.10M
Annual income
$33,761,850,938,174.85/yr
Blended yield
85.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

TBGNF
No analyst data
Altman Z
-23.0
Piotroski
2/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+16.5% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TBGNF buys
0
VICI buys
0
No recent congressional trades found for TBGNF or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTBGNFVICI
Forward yield1176.47% ✓6.57%
Annual dividend / share$2.00 ✓$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3% ✓
Portfolio after 10y$78814195.20M ✓$988.8K
Annual income after 10y$67,523,701,253,088.38 ✓$623,261.32
Total dividends collected$77969765.27M ✓$948.4K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: TBGNF vs VICI ($10,000, DRIP)

YearTBGNF PortfolioTBGNF Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$128,347$117,647.06$11,368$948.43+$117.0K → TBGNF
2$1,548,514$1,411,182.61$13,339$1,493.16+$1.54M → TBGNF
3$17,569,052$15,912,142.01$16,326$2,426.21+$17.55M → TBGNF
4$187,523,354$168,724,468.35$21,123$4,112.15+$187.50M → TBGNF
5$1,883,716,681$1,683,066,692.55$29,379$7,368.23+$1883.69M → TBGNF
6$17,816,329,317$15,800,752,468.33$44,804$14,191.64+$17816.28M → TBGNF
7$158,731,384,105$139,667,911,735.60$76,658$29,972.12+$158731.31M → TBGNF
8$1,332,782,916,056$1,162,940,335,063.89$150,894$71,015.81+$1332782.77M → TBGNF
9$10,551,863,503,163$9,125,785,782,982.70$350,814$193,582.47+$10551863.15M → TBGNF
10$78,814,195,201,473$67,523,701,253,088.38$988,809$623,261.32+$78814194.21M → TBGNF

TBGNF vs VICI: Complete Analysis 2026

TBGNF — Stock

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

Full TBGNF Calculator →

VICI — REIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this TBGNF vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TBGNF vs SCHDTBGNF vs JEPITBGNF vs OTBGNF vs KOTBGNF vs MAINTBGNF vs NNNTBGNF vs EPRTTBGNF vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.